In Vitro Activities of Ertapenem and Imipenem against Clinical Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae Collected in Military Teaching Hospital Mohammed V of Rabat

Abstract EN

Objective.

To study the sensitivity level of extended spectrum beta-lactamase-producing Enterobacteriaceae to Carbapenems (Imipenem, Ertapenem) marketed in Morocco and discusses the place of Ertapenem in the treatment of extended spectrum-beta-lactamase-producing.

Materials and Methods.

A retrospective study of 110 extended spectrum beta-lactamase-producing Enterobacteriaceae.

Isolates obtained from blood cultures, superficial and deep pus, and catheters were conducted.

The minimum inhibitory concentrations of Imipenem and Ertapenem were done by the E-test.

The modified Hodge test was conducted for resistant or intermediate strains.

Results.

99.1% of isolates were susceptible to Imipenem.

For Ertapenem, 4 were resistant and 4 intermediate.

The modified Hodge test was positive for all 08 isolates.

A minimum inhibitory concentration comparison of K.

pneumoniae, E.

cloacae, and E.

coli for Imipenem has noted a significant difference between E.

cloacae on one hand and E.

coli, K.

pneumoniae on the other hand (P<0.01).

No significant difference was noted for minimum inhibitory concentration of Ertapenem.

Conclusion.

Our results confirm in vitro effectiveness of Ertapenem against extended spectrum beta-lactamase-producing Enterobacteriaceae as reported elsewhere.

However, the emergence of resistance to Carbapenems revealed by production of carbapenemases in this study confirmed a necessary bacteriological documented infection before using Ertapenem.